Loading...
Loading...
In a report released earlier today, Wedbush Securities Inc. reiterated its Outperform rating for Medivation, Inc.
MDVN and raised its price target from $81.00 to $86.00.
Wedbush went on to say “MDVN announced Q1:12 EPS of $0.01, due to recognition of upfront and milestone payments from former partner Pfizer, and current partner Astellas. The company ended the quarter with $380M in cash, after netting $251M from a convertible debt offering in the quarter. Cash burn was guided to $155-$170M, we estimate $173M in burn for 2012.”
Medivation, Inc. closed yesterday at $77.72.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in